ESSA Pharma Inc.
EPIX
$1.72
$0.010.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 44.69% | 22.22% | -0.25% | -6.88% | -12.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.58% | 7.12% | 5.51% | 5.11% | -10.84% |
| Operating Income | -14.58% | -7.12% | -5.51% | -5.11% | 10.84% |
| Income Before Tax | -20.57% | -7.38% | -0.65% | 4.57% | 21.47% |
| Income Tax Expenses | -- | -- | 100.00% | 100.00% | 101.43% |
| Earnings from Continuing Operations | -20.56% | -7.37% | -0.89% | 4.21% | 21.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.56% | -7.37% | -0.89% | 4.21% | 21.20% |
| EBIT | -14.58% | -7.12% | -5.51% | -5.11% | 10.84% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -19.91% | -6.92% | -0.58% | 4.37% | 21.28% |
| Normalized Basic EPS | -19.87% | -6.90% | -0.33% | 4.73% | 21.54% |
| EPS Diluted | -19.91% | -6.92% | -0.58% | 4.37% | 21.65% |
| Normalized Diluted EPS | -19.87% | -6.90% | -0.33% | 4.73% | 21.54% |
| Average Basic Shares Outstanding | 0.54% | 0.42% | 0.28% | 0.14% | 0.10% |
| Average Diluted Shares Outstanding | 0.54% | 0.42% | 0.28% | 0.14% | 0.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |